
USD
+$0.00
(+0.00%
)At Close (As of Oct 24, 2025)
$89.21B
Market Cap
17.6
P/E Ratio
2.49
EPS
$61.00
52 Week High
$42.38
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $27B |
| Total Revenue | $48B |
| Cost Of Revenue | $21B |
| Costof Goods And Services Sold | $21B |
| Operating Income | $9.7B |
| Selling General And Administrative | $6.4B |
| Research And Development | $9.8B |
| Operating Expenses | $18B |
| Investment Income Net | - |
| Net Interest Income | -$1.9B |
| Interest Income | $1.5B |
| Interest Expense | $1.9B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $9.6B |
| Income Before Tax | -$8.4B |
| Income Tax Expense | $554M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$8.9B |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$6.4B |
| Ebitda | $3.2B |
| Net Income | -$8.9B |
| Field | Value (USD) |
|---|---|
| Total Assets | $93B |
| Total Current Assets | $30B |
| Cash And Cash Equivalents At Carrying Value | $10B |
| Cash And Short Term Investments | $10B |
| Inventory | $2.6B |
| Current Net Receivables | $14B |
| Total Non Current Assets | $63B |
| Property Plant Equipment | $8.4B |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $24B |
| Intangible Assets Excluding Goodwill | $24B |
| Goodwill | $22B |
| Investments | - |
| Long Term Investments | $2.5B |
| Short Term Investments | $513M |
| Other Current Assets | $1.9B |
| Other Non Current Assets | - |
| Total Liabilities | $76B |
| Total Current Liabilities | $24B |
| Current Accounts Payable | $3.6B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2.2B |
| Total Non Current Liabilities | $52B |
| Capital Lease Obligations | $1.6B |
| Long Term Debt | $48B |
| Current Long Term Debt | $2B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $51B |
| Other Current Liabilities | $16B |
| Other Non Current Liabilities | $522M |
| Total Shareholder Equity | $16B |
| Treasury Stock | - |
| Retained Earnings | $15B |
| Common Stock | $292M |
| Common Stock Shares Outstanding | $2B |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $15B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $9.6B |
| Capital Expenditures | $1.2B |
| Change In Receivables | - |
| Change In Inventory | -$486M |
| Profit Loss | - |
| Cashflow From Investment | -$21B |
| Cashflow From Financing | $5.1B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $4.9B |
| Dividend Payout Common Stock | $4.9B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $0 |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$8.9B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $27B |
| Total Revenue | $48B |
| Cost Of Revenue | $21B |
| Costof Goods And Services Sold | $21B |
| Operating Income | $9.7B |
| Selling General And Administrative | $6.4B |
| Research And Development | $9.8B |
| Operating Expenses | $18B |
| Investment Income Net | - |
| Net Interest Income | -$1.9B |
| Interest Income | $1.5B |
| Interest Expense | $1.9B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $9.6B |
| Income Before Tax | -$8.4B |
| Income Tax Expense | $554M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$8.9B |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$6.4B |
| Ebitda | $3.2B |
| Net Income | -$8.9B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-10-03 |
| Declaration Date | 2025-09-17 |
| Record Date | 2025-10-03 |
| Payment Date | 2025-11-03 |
| Amount | 0.62 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Bristol-Myers Squibb Company (BMY) is a prominent global biopharmaceutical leader headquartered in New York City, renowned for its innovation in the discovery and delivery of transformative medicines. With a strategic focus on key therapeutic areas such as oncology, cardiovascular disease, immunology, and hematology, the company boasts a diverse portfolio that includes several well-established, market-leading therapies. BMS's dedication to addressing significant unmet medical needs, coupled with a robust development pipeline and strategic collaborations, positions it advantageously within the competitive pharmaceutical landscape. The company's ongoing commitment to advancing healthcare through cutting-edge research and development underscores its potential for sustained growth and impact in the biopharmaceutical sector.